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Porcine reproductive and respiratory syndrome virus (PRRSV) glycoprotein 5 (GP5) is the most abundant
envelope glycoprotein and a major inducer of neutralizing antibodies in vivo. Three putative N-linked glyco-
sylation sites (N34, N44, and N51) are located on the GP5 ectodomain, where a major neutralization epitope
also exists. To determine which of these putative sites are used for glycosylation and the role of the glycan
moieties in the neutralizing antibody response, we generated a panel of GP5 mutants containing amino acid
substitutions at these sites. Biochemical studies with expressed wild-type (wt) and mutant proteins revealed
that the mature GP5 contains high-mannose-type sugar moieties at all three sites. These mutations were
subsequently incorporated into a full-length cDNA clone. Our data demonstrate that mutations involving
residue N44 did not result in infectious progeny production, indicating that N44 is the most critical amino acid
residue for infectivity. Viruses carrying mutations at N34, N51, and N34/51 grew to lower titers than the wt
PRRSV. In serum neutralization assays, the mutant viruses exhibited enhanced sensitivity to neutralization by
wt PRRSV-specific antibodies. Furthermore, inoculation of pigs with the mutant viruses induced significantly
higher levels of neutralizing antibodies against the mutant as well as the wt PRRSV, suggesting that the loss
of glycan residues in the ectodomain of GP5 enhances both the sensitivity of these viruses to in vitro
neutralization and the immunogenicity of the nearby neutralization epitope. These results should have great
significance for development of PRRSV vaccines of enhanced protective efficacy.
Porcine reproductive and respiratory syndrome virus (PRRSV)
belongs to the family Arteriviridae within the order Nidovirales
which also includes equine arteritis virus (EAV), lactate dehy-
drogenase-elevating virus (LDV), and simian hemorrhagic fe-
ver virus. The viral genome is a linear, positive-stranded RNA
molecule of approximately 15.0 kb in length and possesses a
cap structure at the 5 end and a poly(A) tail at the 3 end.
Eight open reading frames (ORFs) are in the viral genome (9,
34). The first two open reading frames (ORF1a and ORF1ab)
encode viral nonstructural (NS) polyproteins that are involved
in polyprotein processing and genome transcription and repli-
cation (47). The viral structural proteins, encoded in ORFs 2 to
7, are expressed from six subgenomic capped and polyadeny-
lated mRNAs that are synthesized as a 3-coterminal nested
set of mRNAs with a common leader sequence at the 5 end.
The major viral envelope protein is glycoprotein 5 (GP5),
which is encoded in ORF5 of the viral genome (29, 35, 36).
GP5 is a glycosylated transmembrane protein of approximately
25 kDa (10, 16, 35). It has a putative N-terminal signal peptide
and possesses three potential N-linked glycosylation sites
which are located in a small ectodomain comprising the first 40
residues of the mature protein (28, 35). In EAV and LDV, the
major envelope glycoprotein forms a disulfide-linked het-
erodimer with the ORF6 gene product, the viral matrix (M)
protein (13, 15, 45). Similar interaction between PRRSV GP5
and M protein has been observed but the mode of interaction
has not been defined yet (12, 28).
It has been postulated that formation of heterodimers of
GP5 and M proteins may play a critical role in assembly of
infectious PRRSV. In addition to its role in virus assembly,
GP5 appears to be involved in entry of the virus into suscep-
tible host cells. GP5 is presumed to interact with the host cell
receptor sialoadhesin (11) for entry into porcine alveolar mac-
rophages, the in vivo target cells for PRRSV. The role of GP5
in receptor recognition is supported by the presence of a major
neutralization epitope in the N-terminal ectodomain (38), im-
plying a central role for the GP5 ectodomain in the infection
process.
The N-linked glycans of the GP5 ectodomain may be critical
for proper functioning of the protein. N-linked glycosylation,
in general, is important for correct folding, targeting, and bi-
ological activity of proteins (17–19, 51, 55). In many enveloped
viruses, the envelope proteins are modified by the addition of
sugar moieties and the N-linked glycosylation of envelope pro-
tein plays diverse functions in viral glycoproteins such as re-
ceptor binding, membrane fusion, penetration into cells, and
virus budding (6, 14). Recent studies have demonstrated the
role of N-linked glycosylation of Hantaan virus glycoprotein in
protein folding and intracellular trafficking (43) as well as in
the biological activity and antigenicity of influenza virus hem-
agglutinin (HA) protein (1). Furthermore, it has become evi-
dent that glycosylation of viral envelope proteins is a major
mechanism for viral immune evasion and persistence used by
several different enveloped viruses to escape, block, or mini-
mize the virus-neutralizing antibody response. Examples of this
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effect have been reported for simian immunodeficiency virus
(40) and human immunodeficiency virus type 1 (50), hepatitis
B virus (25), and influenza virus (44) and more importantly, in
the case of the arterivirus LDV (8).
Recently the development of reverse genetic systems for
PRRSV has been reported from several laboratories, including
ours (33, 37, 48, 49). Evidently, mutational studies with infec-
tious clones have led to a better understanding of the mecha-
nisms of transcription and replication of the viral genome of
arteriviruses (46). Thus, in order to examine the importance
of N-linked glycosylation in the biological activity of GP5 of
PRRSV in generating infectious virus or eliciting neutralizing
antibodies in vivo, we have constructed a series of mutant GP5
proteins in which each of the potential N-linked glycosylation
sites has been mutated either individually or in various com-
binations. The resulting mutant proteins were examined for
their glycosylation pattern and role in infectious virus recovery
and in cross neutralization by antibodies raised, through ex-
perimental inoculations, against the wild-type (wt) PRRSV
and against the mutant viruses. Our data show that all three
putative glycosylation sites are used for glycosylation with high-
mannose-type glycans and glycosylation of GP5 protein at res-
idue 44 is critical for recovery of infectious PRRSV. Very
importantly, our data from neutralization and antibody re-
sponse studies indicate that natural infection with PRRSV may
involve an immune evasion based on glycan-shielding mecha-
nisms as was previously described for other viruses, helping to
explain the rather ineffective protective humoral immune re-
sponse that is observed in PRRSV-infected animals (31, 38).
MATERIALS AND METHODS
Cells, media, and antibodies. MARC-145 (23) cells were propagated in Dul-
becco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS) and 100 units of penicillin, 20 units of streptomycin, and 20 units of
kanamycin per ml of growth medium. These cells were used for RNA electro-
poration, virus infection, viral growth, and plaque assays. The baby hamster
kidney (BHK-21) cells were maintained in minimal essential medium (MEM)
with Earl’s salt containing 5% FBS and the above-mentioned antibiotics.
BHK-21 cells were used for transient expression of GP5 followed by either
immunofluorescence assays or radiolabeling and immunoprecipitation experi-
ments. All cells were maintained at 37°C and 5% CO2. Rabbit polyclonal anti-
bodies to the PRRSV GP5 and M proteins were kindly provided by Carl A.
Gagnon (University of Quebec, Montreal, Canada). The monoclonal antibody
(SDOW17) against nucleocapsid protein (N) was purchased from National Vet-
erinary Services Laboratories (Ames, IA). The anti-mouse Alexa-488-labeled
antibody was obtained from Molecular Probes (Eugene, OR).
Genetic manipulation of plasmids encoding GP5 and PRRSV infectious clone.
The full-length PRRSV infectious cDNA clone (FL-12) in pBR322 (49) was
digested with EcoRV and BstZ17I restriction enzymes and the 4.9-kbp frag-
ment encompassing the majority of ORF2, complete ORFs 3 to 7, and the entire
3 untranslated region (UTR) of PRRSV was cloned into pBR322 using the same
enzyme sites. This intermediate plasmid served as the template for mutagenesis
to introduce mutations at the potential N-linked glycosylation sites (N34, N44,
and N51) within GP5 (Fig. 2).
Mutagenesis was carried out using overlap extension PCR with synthetic
primers (Table 1), Pfu polymerase (Stratagene), and standard techniques (4, 20,
42). The PCR product was digested with BsrGI and BstEII restriction enzymes
and replaced back in the intermediate plasmid. Clones containing the desired
mutations were identified and confirmed by sequencing. The entire coding region
of GP5 was sequenced to ensure that additional mutations were not present in
the clones. The EcoRV-PacI fragment from the intermediate plasmid containing
mutations in the GP5 coding region was moved back into the full-length cDNA
clone using the same restriction enzyme sites. The GP5 coding region in the
full-length clones was again sequenced with PRRSV-specific internal primers to
confirm the presence of the mutations.
The wt GP5 and individual mutants were cloned in a bicistronic vector (GP5-
IE-M) where GP5 is the first cistron followed by the encephalomyocarditis virus
(EMCV) internal ribosome entry site (IRES) (21) and M coding sequences (Fig.
1A). To construct this plasmid, a DNA fragment encompassing the entire IRES
element of EMCV (IE) was released from the pIRES2-EGFP (Clontech) vector
using BamHI and NcoI restriction enzymes. The fragment was treated with mung
bean nuclease (New England BioLabs) and cloned in the pGEM3 (Promega)
vector digested with SmaI to obtain the vector pGEM3-IE. The full-length GP5
coding region was PCR amplified using a forward primer (GP5-For) that con-
tained an EcoRI enzyme site and Kozak sequence followed by ATG and GP5
sequences and a reverse primer (GP5-Rev) (Table 1) containing an EcoRI
enzyme site. The PCR fragment was cloned at the unique EcoRI site in the
pGEM3-IE vector just upstream of IE so that the coding sequence of GP5 is
under the control of the T7 RNA polymerase promoter.
The resulting plasmid (pGEM3-GP5-IE) was then used to clone the coding
region of the M protein. To this end, the M coding region was PCR amplified
using primer pairs (M-For and M-Rev) (Table 1) containing BamHI and SphI
restriction enzyme sites and cloned in pGEM3-GP5-IE at the corresponding
sites. The GP5 and M coding region in the resulting plasmid (GP5-IE-M) was
sequence confirmed. The IE and M coding region was deleted from GP5-IE-M to
generate plasmid pGEM3-GP5, which expresses only GP5 protein in transfected
cells. The full-length GP5 coding region was also cloned in a cytomegalovirus
promoter-driven vector (pcDNA 3.0; Clontech) for complementation studies.
In vitro transcription and electroporation. The full-length plasmids were di-
gested with AclI and linearized DNA was used as the template to generate
capped RNA transcripts using the mMESSAGE mMACHINE Ultra T7 kit as
TABLE 1. Primers used in this studya
Primer Nucleotide sequence
GP5-For..............................................................5 GCCGGAATTCGGAGCCGCCGCCACCATGTTGGGGAGATGCTTGAC 3
GP5-Rev.............................................................5 CCCCGAATTCCTAAAGACGACCCCATTGTTC 3
M-For .................................................................5 ATATATGGATCCGCCACCATGGGGTCGTCTTTAGACGAC 3
M-Rev.................................................................5 ATATATGCATGCTTATTTGGCATATTTGACAAGG 3
GP5-N34A-For ..................................................5 GCCAACAGCGCCAGCAGCTCTC 3
GP5-N44A-For ..................................................5 GTTGATTTACGCCTTGACGCTATG 3
GP5-N51A-For ..................................................5 GTGAGCTGGCTGGCACAGATTG 3
GP5-N34/44A-For .............................................5 GCCAACAGCGCCAGCAGCTCTCATCTTCAGTTGATTTACGCCTTGACGCTATG 3
GP5-N44/51A-For .............................................5 GTTGATTTACGCCTTGACGCTATGTGAGCTGGCTGGCACAGATTG 3
GP5-N34/51A-For .............................................5 GCCAACAGCGCCAGCAGCTCTCATCTTCAGTTGATTTACAACTTGACGCTATGTGAG
CTGGCTGGCACAGATTG 3
GP5-N34/44/51A-For........................................5 GCCAACAGCGCCAGCAGCTCTCATCTTCAGTTGATTTACGCCTTGACGCTATGTGAG
CTGGCTGGCACAGATTG 3
PRRSV-13177-For ............................................5 CTACCAACATCAGGTCGATGGCGG 3
PRRSV-14473-Rev ...........................................5 GTCGGCCGCGACTTACCTTTAGAG 3
a Underlining indicates mutations. Restriction enzyme sites incorporated in the primers are shown in bold; the initiation codons for the GP5 and M proteins are
shown in bold italics.
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per the manufacturer’s (Ambion, Austin, TX) recommendations and as de-
scribed earlier (48, 49). The reaction mixture was treated with DNase I to digest
the DNA template and extracted with phenol and chloroform and finally pre-
cipitated with isopropanol. The integrity of the in vitro transcripts was analyzed
by glyoxal-agarose gel electrophoresis followed by ethidium bromide staining.
MARC-145 cells were electroporated with approximately 5.0 g of in vitro
transcripts along with 5.0 g of total RNA isolated from MARC-145 cells. About
2  106 cells in 400 l of DMEM containing 1.25% dimethyl sulfoxide were
pulsed once using a Bio-Rad Gene Pulser Xcell at 250 V and 950 F in a 4.0-mm
cuvette. The cells were diluted in normal growth medium and plated in a 60-mm
cell culture plate. A small portion of the electroporated cells was plated in a
24-well plate to examine expression of N protein at 48 h postelectroporation,
which would indicate genome replication and transcription. Once expression of
N protein is confirmed using an indirect immunofluorescence assay, the super-
natant from bulk of the electroporated cells in the 60-mm plate was collected at
48 h postelectroporation, clarified, and passed onto naı¨ve MARC-145 cells. The
infected cells were observed for cytopathic effect along with the expression of N
protein using immunofluorescence assay. The supernatants from infected cells
showing both cytopathic effect and positive fluorescence were considered to
contain infectious virus. After confirmation, the virus stock was grown and frozen
at 80°C in small aliquots for further studies. In all the experiments, FL-12,
containing the wt PRRSV genome, and FL-12pol, containing the polymerase-
defective PRRSV genome (48, 49), were used as controls.
Metabolic radiolabeling and analyses of proteins. BHK-21 cells in six-well
plates were infected with recombinant vaccinia virus (vTF7-3) at a multiplicity of
infection (MOI) of 3.0 and subsequently transfected with the bicistronic plasmid
DNA encoding wt or various mutant GP5s under the T7 RNA polymerase
promoter. DNA transfection was carried out using Lipofectamine2000 as per the
manufacturer’s protocol (Life Technologies). At 16 h posttransfection, cells were
washed twice with phosphate-buffered saline (PBS) and starved in methionine-
and cysteine-free DMEM for 1 hour and radiolabeled with 0.6 ml of methionine-
and cysteine-free DMEM containing 100 Ci of Expre35S35S protein labeling
mix (NEN Life Sciences, MA) per ml of medium for 3 hours. Following radio-
labeling, the cells were washed in cold PBS three times and cell extracts were
prepared in 300 l of radioimmunoprecipitation assay (RIPA) buffer (10 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate
[SDS], 1% sodium deoxycholate, and 1 protease inhibitor). The clarified cell
extracts were incubated overnight at 4°C with rabbit anti-GP5 or anti-M protein
antibody. A slurry of approximately 4.0 mg of protein A-Sepharose (Pharmacia,
Uppsala, Sweden) in 100 l RIPA buffer was added and further incubated for
2 h. The immunoprecipitated complexes were washed three times with 500 l of
RIPA buffer and used for further analysis.
For pulse-chase analysis, infected and transfected cells were labeled for 2 h as
described above and either harvested immediately or washed twice with warm
PBS and maintained in DMEM containing a 100-fold excess of unlabeled me-
thionine for 2 or 4 h before harvesting. In PRRSV-infected infected cells, the
pulse-chase experiment was performed similarly at 48 h postinfection.
For endoglycosidase H (Endo H) treatment, the immunoprecipitated com-
plexes were resuspended in 20 l of 1 denaturing buffer (0.5% SDS, 1.0%
-mercaptoethanol) and boiled for 10 min. The supernatant was collected, ad-
justed to 1 G5 buffer (0.05 M sodium citrate, pH 5.5), and incubated for 16 h
at 37°C with 100 units of Endo H (New England Biolabs). The undigested control
samples were processed similarly but no Endo H was added. Following Endo H
digestion, the samples were mixed with an equal volume of 2 SDS-polyacryl-
amide gel electrophoresis (PAGE) sample buffer, boiled for 5 min, and resolved
by SDS–12% PAGE under denaturing conditions along with protein marker
(Protein Plus Precision Standard; Bio-Rad). The gel was fixed with 10% acetic
acid for 15 min, washed three times with water, treated with 0.5 M sodium
salicylate for 30 min, dried, and finally exposed to X-ray film at 70°C. For
peptide N-glycosidase F (PNGase F) (New England Biolabs) digestion, immu-
noprecipitated complexes were resuspended in 1 G7 buffer (0.05 M sodium
phosphate, pH 7.5, 1.0% NP-40) and digestion was performed by incubating for
16 h at 37°C with 2 units of the enzyme. To examine synthesis of GP5 in the
presence of tunicamycin (Sigma), transfected cells were treated with 2.0 g of
tunicamycin per ml of medium for 1 hour and radiolabeling was performed in the
presence of the drug for 3 h as above.
For obtaining radiolabeled extracellular virions or intracellular virus-expressed
GP5, MARC-145 cells were infected with wt or mutant PRRSVs. At 48 h
postinfection, the cells were starved for 1 hour and radiolabeled with 100 Ci of
Expre35S35S protein labeling mix per ml of medium containing 90% methionine-
and cysteine-free DMEM and 10% regular DMEM for 24 h. Following labeling,
the culture supernatant was harvested and cleared of cell debris and the extra-
cellular virions were pelleted at 100,000  g for 3 h at 4°C. The viral pellets were
resuspended in 200 l of RIPA buffer and immunoprecipitated with anti-GP5
antibody and the proteins were examined with or without Endo H treatment. For
immunoprecipitation of intracellular virus-expressed GP5, infection was carried
out as described above and at 24 h postinfection, the cells were starved for 1 hour
and radiolabeled as described above for 2 h prior to preparing cell extracts.
Viral growth kinetics and plaque assay. MARC-145 cells were infected with
mutant or wt PRRSV at an MOI of 3.0 PFU per cell and incubated at 37°C in
an incubator. At various time points postinfection, aliquots of culture superna-
tants from infected cells were collected and the virus titer in the supernatants was
determined and expressed as 50% tissue culture infectious dose per ml (TCID50/
ml). To examine the plaque morphology of mutant viruses, the plaque assay was
performed using MARC-145 cells. Cells were infected with 10-fold serial dilu-
tions of individual viruses for 1 hour at 37°C. The infected cell monolayer was
washed with PBS and overlaid with DMEM–5% FBS containing 0.8% SeaPlaque
agarose (FMC Bioproducts, ME). After 96 h, the agarose plugs were removed
and the cell monolayer was incubated with staining solution (20% formaldehyde,
9.0% ethanol, and 0.1% crystal violet) for 30 min at room temperature. The cells
were gently washed with water to remove excess dye and air dried to examine and
count the plaques.
Complementation of virus recovery by expressing wt GP5 in trans. BHK-21
cells were transfected with pcDNA-GP5. At 40 h posttransfection, the cells were
harvested and electroporated with capped in vitro transcripts derived from full-
length PRRSV cDNA encoding mutant GP5. The electroporated cells were
diluted with fresh medium and plated in a six-well plate. The supernatant from
the electroporated cells was collected at 48 h postelectroporation, centrifuged to
FIG. 1. Transient expression of PRRSV GP5 and M protein. (A)
Schematic of the bicistronic construct showing the GP5 and M coding
regions flanking the IRES from EMCV (IE). The coding regions are
under the control of the T7 RNA polymerase promoter (black rect-
angle) present immediately upstream of the GP5 coding region. The
bent arrow shows the position and direction of transcription by T7
RNA polymerase from the vector. (B) Expression of GP5 and M
proteins in cells transfected with the bicistronic vector. Mock-trans-
fected (lane 1) or plasmid-transfected cells (lanes 2 to 7) were radio-
labeled as described in Materials and Methods and immunoprecipi-
tated with anti-GP5 antibody (lanes 1 to 5) or anti-M antibody (lanes
6 and 7). Immunoprecipitated proteins were left untreated () (lanes
1, 2, 6, and 7) or treated () with Endo H (lane 3) or PNGase F (lane
4) and analyzed by electrophoresis. Lane 5 contains immunoprecipi-
tated proteins from transfected cells treated or not with tunicamycin.
The mobility of proteins is shown in kilodaltons. The asterisk identifies
a cellular protein that coimmunoprecipitates with anti-M antibody.
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remove cell debris, and used to infect naı¨ve MARC-145 cells. The infected
MARC-145 cells were examined at 48 h postinfection for expression of N protein
by immunofluorescence assay as described above. The number of positive cells
was counted to assign the number of pseudoparticles produced in the superna-
tant. The average number of positive cells was calculated from three independent
experiments and is presented as the number of pseudoparticles produced per
microgram of in vitro-transcribed RNA transfected into the cells.
Serum neutralization assays. The titer of PRRSV-neutralizing antibodies in a
serum sample was determined using the fluorescence focus neutralization assay
described previously (54). Serial dilutions of test sera were incubated for 60 min
at 37°C in the presence of 200 TCID50 of the challenge virus, which consisted of
either FL12 (wt PRRSV) or any of the GP5 mutant-encoding viruses FL-N34A,
FL-N51A, and FL-N34/51A in DMEM containing 5% FBS. The mixtures were
added to 96-well microtitration plates containing confluent MARC-145 cells
which had been seeded 48 h earlier. After incubation for 24 h at 37°C in a
humidified atmosphere containing 5% CO2, the cells were fixed for 10 min with
a solution of 50% methanol and 50% acetone. After extensive washing with PBS,
the expression of N protein of PRRSV was detected with monoclonal antibody
SDOW17 (36) using a 1:500 dilution, followed by incubation with fluorescein
isothiocyanate-conjugated goat anti-mouse immunoglobulin G (Sigma) at a
1:100 dilution. Neutralization titers were expressed as the reciprocal of the
highest dilution that inhibited 90% of the foci present in the control wells.
Experimental inoculation of pigs with GP5 mutants and wt PRRSV. High-titer
stocks (obtained through three passages in MARC-145 cells) of the GP5 mutant
viruses (FL-N34A, FL-N51A, and FL-N34/51A) and FL-12 (wt PRRSV) were
used to infect young pigs. Twenty-one-day-old, recently weaned pigs were pur-
chased from a specific-pathogen-free herd with a certified record of absence of
PRRSV infection. All animals were negative for anti-PRRSV antibodies as
tested by enzyme-linked immunosorbent assay (Iddex Labs, Portland, ME).
Three pigs per group were infected with either FL-12 wt PRRSV or mutants
FL-N34A, FL-N51A, and FL-N34/51A. In all cases, the inoculum consisted of
105 TCID50 diluted in 2 ml and was administered intramuscularly in the neck.
The rectal temperatures of the inoculated animals were monitored for 15 days
postinoculation. Viremia was measured by regular isolation on MARC-145 cells
at days 4, 7, and 14 postinoculation. Serum samples were drawn weekly for a total
of 48 days postinoculation. The serum samples were used to detect homologous
and heterologous cross-neutralization titers for each of the mutants and wt
PRRSV.
RESULTS
Expression and characterization of PRRSV GP5. GP5 of
PRRSV strain 97-7895 (49) has three putative N-linked glyco-
sylation sites (N34, N44, and N51). To examine the glycosyla-
tion pattern of GP5, we first generated a bicistronic vector in
which the coding regions of the GP5 and M proteins flanking
the EMCV IRES were placed under the control of the T7
RNA polymerase promoter (Fig. 1A). The rationale for con-
structing the bicistronic vector is that the GP5 and M proteins
are known (for LDV and EAV) or postulated (for PRRSV) to
interact with each other (32) and that such interactions may be
important for protein folding, glycosylation, intracellular trans-
port, and/or other biological activities of GP5 (45).
Transient expression of GP5 and M by transfection of the
bicistronic plasmid followed by radiolabeling and immunopre-
cipitation with anti-GP5 antibody revealed two major protein
species. The protein species migrating with a mass of 25.5
kDa is the fully glycosylated form of GP5 (Fig. 1B, lane 2).
Since each N-linked glycosylation adds 2.5 kDa of molecular
mass to a protein (24), this indicates that all three potential
glycosylation sites may be used for glycosylation of GP5. The
19.0-kDa protein species is the viral M protein, since it was
also was specifically immunoprecipitated with anti-M antibody
(Fig. 1B, lane 7). The results indicate that the GP5 and M
proteins interact with each other in cells expressing both pro-
teins, as both proteins were coimmunoprecipitated with anti-
GP5 antibody as well as anti-M antibody.
Upon treatment with Endo H, an enzyme that removes
high-mannose-type oligosaccharide chains, the size of GP5 was
reduced to 17 kDa, whereas the size of the M protein re-
mained unchanged (Fig. 1B, lane 3). Treatment of GP5 with
PNGase F (Fig. 1B, lane 4), an enzyme that removes all types
of sugars from the protein backbone, or synthesis of GP5 in the
presence of tunicamycin (Fig. 1B, lane 5) resulted in a protein
that migrated with slightly faster electrophoretic mobility than
the protein with Endo H treatment. This is expected, since
tunicamycin treatment or digestion with PNGase F would gen-
erate unglycosylated proteins, whereas Endo H treatment
would result in proteins that retain N-acetylglucosamine resi-
dues at each of the N-linked glycosylation sites. No difference
in the Endo H sensitivity of GP in the presence or absence of
M protein was observed (data not shown).
Furthermore, in cells transfected with the plasmid encoding
GP5 alone, in addition to the25.5-kDa and17-kDa protein
species, a GP5 molecule with a molecular mass of 19 kDa
was also detected (data not shown). We reason that the 19-
kDa protein, which comigrates with the M protein, is the un-
glycosylated form of full-length GP5 and that the 17-kDa
species is the amino-terminal signal-cleaved unglycosylated
form of the protein. It is of note that a prominent protein
species of 30-kDa molecular mass (identified by the asterisk
in Fig. 1B) was detected with anti-M antibody. The identity of
this protein is not known but it could be a cellular protein that
interacts with the M protein.
The results from the above studies suggest that the ungly-
cosylated and fully glycosylated forms of GP5 possess apparent
molecular sizes of 19 kDa and 25.5 kDa, respectively. The
17-kDa protein species is likely generated by cleavage of the
amino-terminal signal sequence. It appears that all three po-
tential glycosylation sites are used to generate the fully glyco-
sylated form of GP5. The glycan moieties added to these sites
are of the high-mannose type since they are sensitive to diges-
tion by Endo H. In addition, the results indicate that both
unglycosylated and fully glycosylated forms of GP5 appear to
interact with the M protein.
Analysis of N-linked glycosylation sites used for glycosyla-
tion of GP5. To more precisely determine whether all or some
of the potential N-linked glycosylation sites in GP5 are used for
addition of sugar moieties, a panel of mutants in which all three
potential glycosylation sites, N34, N44, and N51 (Fig. 2A), were
altered to alanines either individually or in various combinations
were generated in the bicistronic plasmid (Fig. 2B). In plasmid-
transfected cells, the proteins were radiolabeled and immunopre-
cipitated with anti-GP5 antibody. The immune complexes were
either left untreated or treated with Endo H and examined by
SDS-PAGE.
As can be seen from the data presented in Fig. 2C, mutant
GP5 proteins carrying single mutations (N34A, N44A, or
N51A) migrated as 23.0-kDa protein species (lanes 3, 5, and
7, open arrow), which, upon treatment with Endo H, migrated
as 17-kDa protein species (Fig. 2C, lanes 4, 6, and 8, aster-
isk), similar to the wt GP5 after Endo H treatment (Fig. 2C,
lane 2). The minor differences in electrophoretic mobility of
the proteins are most likely reflective of the fact that the wt
protein would retain all three N-acetylglucosamine residues
following Endo H treatment compared to the single mutants,
which would contain two such residues. The double mutants
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(N34/44A, N44/51A, and N34/51A) produced protein species
that migrated close to 20.5 kDa (Fig. 2C, lanes 9, 11, and 13,
gray arrow) and upon Endo H treatment, the size of the pro-
teins was reduced to 17 kDa (Fig. 2C, lanes 10, 12, and 14).
The triple mutant (N34/44/51A) generated a protein that mi-
grated as 19.0-kDa protein (Fig. 2C, lane 15) and was resis-
tant to Endo H digestion (Fig. 2C, lane 16). To unequivocally
ascertain that the triple mutant protein was synthesized, we
examined expression of the triple mutant GP5 in the absence
of M protein. As can be seen from the results in Fig. 2D, the
triple mutant was synthesized in transfected cells (lane 4) as a
19-kDa protein, which was resistant to Endo H (lane 5).
Thus, from the above mutational studies, it is clear that all
the three potential glycosylation sites are used for glycosylation
to generate fully mature PRRSV GP5. It appears that all three
glycosylation sites are modified by high-mannose-type glycan
moieties.
Recovery of infectious PRRSV with GP5 mutants. To assess
the importance of N-linked glycosylation in the generation of
infectious PRRSV, the coding regions of the mutant GP5 pro-
teins were inserted into the full-length cDNA clone (49).
Capped in vitro transcripts produced from the clones were
electroporated into MARC-145 cells and generation of infec-
tious PRRSV was examined. Our results showed that infec-
tious virus was readily recovered from the cells electroporated
with full-length transcripts containing mutations at N34, N51,
and N34/51. However, under similar conditions for virus re-
covery, repeated attempts to recover other mutant viruses were
unsuccessful.
Although the growth kinetics of the recovered viruses were
similar to that of the wt virus, the overall yield of viruses
FL-N34A and FL-N51A, containing mutations at N34 and
N51, respectively, was approximately one log less in MARC-
145 cells, while that of FL-N34/51A with the double mutation
(N34/51A) was almost 1.5 log less than that of the wt PRRSV
(Fig. 3A). Reverse transcription-PCR amplification of RNA
from infected cells followed by nucleotide sequencing indi-
cated that these viruses are stable and contained the desired
mutations and no other mutations were detected in the entire
GP5 region (data not shown).
The viral plaque assay was performed on MARC-145 cells to
monitor the plaque phenotype of the mutant viruses. The ma-
jority of the plaques generated by wt PRRSV were clear and
distinct, while the mutant viruses produced plaques that had
different phenotypes. The FL-N34A, FL-N51A, and FL-N34/
51A viruses generated some plaques that were less distinct and
FIG. 2. Glycosylation analysis of wt GP5 and its mutants in transfected cells. (A) Schematic of the bicistronic vector and PRRSV GP5 with the
three putative glycosylation sites at amino acid positions 34, 44, and 51 shown. (B) Various mutants used in the present study. (C) Expression of
wt and mutant GP5 and their sensitivity to Endo H. The experiment was performed as described in the legend to Fig. 1; proteins were
immunoprecipitated with anti-GP5 antibody, digested with Endo H () or left undigested (), and analyzed by electrophoresis. Mutant GP5
proteins are shown by open and shaded arrows. The protein band (17 kDa) identified by the asterisk is generated by Endo H digestion of the
wt and mutant GP5 proteins. (D) Expression of the triple mutant GP5 N34/44/51A from plasmids with and without M. Cells were mock transfected
(lane 1) or transfected with plasmids encoding the triple mutant-containing M coding region (GP5-N34/44/51A, lanes 2 and 3) or without the M
coding region (GP5-N34/44/51A*, lanes 4 and 5). Proteins were radiolabeled and detected with anti-GP5 antibody as described above. The mobility
of proteins is shown in kilodaltons on the right.
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many of the cells within these plaques appeared normal. In
addition, the mutant viruses also produced some plaques in
which the viruses failed to clear the cell monolayer (Fig. 3B,
solid arrow). Higher-magnification images (Fig. 3C) of repre-
sentative plaques show that the plaques produced by wt
PRRSV are much bigger than those from the mutant viruses
and that the mutant viruses fail to lyse the cell monolayer in the
plaque. These data indicate that the recovered mutant viruses
are indeed less cytopathic than wt PRRSV.
Since we were unable to recover infectious PRRSV with
mutant templates FL-N44A, FL-N31/44A, FL-N44/51A, and
FL-N31/44/51A, it is possible that mutations in the GP5 coding
region may have affected some other function(s) of the RNA
templates, such as packaging of the genomic RNA into parti-
cles. To address this, we examined whether cells expressing wt
GP5 in trans could support packaging of mutant RNA tem-
plates that are otherwise defective in generating infectious
PRRSV. BHK-21 cells transfected with pcDNA-GP5 were
electroporated with in vitro transcripts and at 48 h postelec-
troporation, the culture supernatants were collected and used
to infect naı¨ve MARC-145 cells to determine the production of
PRRSV pseudoparticles.
If pseudoparticles are generated, one would then expect to
observe expression of the N protein in these infected MARC-
145 cells. The expression of N is only possible when naı¨ve
MARC-145 cells receive full-length encapsidated mutant RNA
genome that sets up replication following entry of the pseudo-
particles into cells. Of all the mutants that could not be recov-
ered previously, we were able to recover pseudoparticles
containing two mutant full-length genomes (FL-N44A and
FL-N34/44A). Multiple attempts to recover pseudoinfectious
particles with the other mutant templates (FL-N44/51A and
FL-N31/44/51A) were unsuccessful.
A quantitative estimation of the number of infectious pseudo-
particles produced from these experiments suggests that ap-
proximately 1,000 particles are produced per microgram of
mutant RNA electroporated into the cells (Fig. 3D). This is
approximately 100-fold less than that obtained with RNA en-
coding wt GP5. The production of such low levels of infectious
pseudoparticles could be due to the fact that only about 5 to
10% of cells that expressed wt GP5 received the full-length
transcripts, as seen by the expression of the N protein in these
cells. It is also possible that low levels of expression of wt GP5
in the transfected cells may have contributed to the low levels
of production of these pseudovirions.
Examination of GP5 incorporated into mutant viruses and
those expressed in infected and transfected cells. To determine
the nature of the GP5 protein incorporated into infectious virions
produced from transfected cells, we generated radiolabeled
PRRSV from cells infected with the wt and mutant viruses. The
extracellular virions present in the culture supernatant were pel-
leted by ultracentrifugation and GP5 present in these virions was
examined by immunoprecipitation using anti-GP5 antibody and
subsequent electrophoretic analysis. The results show that the wt
GP5 incorporated into virions migrated as a broadly diffuse band
of 25- to 27-kDa protein species (Fig. 4A, lane 1), which is
partially resistant to Endo H digestion (lane 2). Mutant GP5
(N34A and N51A) incorporated into virions were sensitive to
Endo H. Based on the sizes of the products generated following
Endo H digestion, it appears that only one glycan moiety in these
single-site mutants is sensitive, while the other is resistant. In
contrast, the double mutant GP5 (N34/51A) was partially resis-
tant to Endo H. Furthermore, Endo H digestion of GP5 from
mutant viruses also produced various amounts of GP5 protein
backbone, indicating that these viruses incorporate GP5 proteins
FIG. 3. Characterization of mutant viruses encoding mutant GP5. (A) Single-step growth kinetics of wt (FL-12) and various mutant PRRSVs
in MARC-145 cells. Cells in six-well plates were infected with PRRSV at an MOI of 3, culture supernatants were collected at the indicated times
after infection, and virus titers were determined. Average titers with standard deviations (error bars) from three independent experiments are
shown. (B) Plaque morphology of mutant viruses. Arrows and arrowheads show plaques that are less clear. Boxes show representative plaques that
have been magnified in succeeding panels. (C) Magnified images of representative plaques from wt PRRSV (FL-WT) and one mutant virus
(FL-N34/51A). (D) trans-Complementation to recover mutant PRRSVs; quantitative analysis of mutant virus recovery from cells expressing wt
GP5 protein. The average yields of viruses from three independent experiments with standard deviations (represented by error bars) are shown.
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that contain Endo H-resistant as well as Endo H-sensitive glycan
moieties.
Since in cells transfected with the bicistronic vector, the wt as
well as the mutant GP proteins were completely Endo H sensitive
(Fig. 1 and 2), we were surprised by the observation that GP5 on
PRRSV virions contained largely Endo H-resistant forms. To
examine if the Endo H-resistant forms of the protein are also
synthesized in infected cells, MARC-145 cells infected with wt or
mutant PRRSV were radiolabeled, and GP5 protein was immu-
noprecipitated with anti-GP5 antibody and analyzed by electro-
phoresis with or without Endo H digestion. The results of such an
experiment are shown in Fig. 4B.
The majority of wt GP5 contained Endo H-resistant glycans
at all three sites (lanes 2 and 3), whereas the two single mutants
contained Endo H-resistant glycans at only one site (lanes 4 to
7). Some of the glycan moieties in the double mutant are
resistant, while others are sensitive to Endo H (Fig. 4B, lanes
8 and 9). Although the pattern of Endo H resistance is similar
to what is observed for virion-associated GP5, it is different
from that observed in cells expressing both GP5 and M pro-
teins (Fig. 1 and 2).
To further determine if the GP5 protein synthesized in
transfected cells is different from that synthesized in PRRSV-
infected cells, we examined the Endo H resistance of GP5 by
pulse-chase experiments. In transfected cells, GP5 synthesized
during a 2-h pulse was completely sensitive to Endo H and
remained fully sensitive to the enzyme even after a 4-h chase
(Fig. 4C), indicating that GP5 remains in the endoplasmic
reticulum or cis-Golgi compartment. However, in PRRSV-
infected cells, GP5 was partially sensitive to Endo H following
a 2-h pulse and the Endo H sensitivity of the protein decreased
with increasing chase times (Fig. 4D). These results indicate
that other viral proteins present in PRRSV-infected cells may
play a role in further modification of glycans on GP5.
Influence of hypoglycosylation of GP5 on PRRSV’s ability to
be neutralized by specific antibodies. The level of glycosylation
FIG. 4. Examination of GP5 incorporated into mutant virions and synthesized in mutant virus-infected cells or in transfected cells. (A)
Radiolabeled virions from culture supernatants of infected cells were pelleted, GP5 protein was immunoprecipitated, treated with Endo H () or
not (), and analyzed by electrophoresis. The positions of wt GP5 without and with Endo H digestion (lanes 1 and 2, respectively) are shown by
white brackets. (B) Cells infected with various mutant viruses were radiolabeled, GP5 was immunoprecipitated, treated with Endo H () or not
(), and analyzed by electrophoresis. The positions of wt GP5 without and with Endo H digestion (lanes 2 and 3, respectively) are shown by white
brackets. (C) Pulse-chase analysis and Endo H sensitivity of GP5 expressed in transfected cells. Cells were transfected with GP5-IE-M, pulse-
labeled for 2 h (2hrP), and subsequently chased for 2 h (2hrC) or 4 h (4hrC). Proteins were immunoprecipitated with anti-GP5 antibody, digested
with Endo H () or not (), and analyzed by electrophoresis as described in Materials and Methods. (D) Pulse-chase analysis and Endo H
sensitivity of GP5 in cells infected with wt PRRSV. The experiment was performed as in panel C. The mobility of proteins is shown in kilodaltons
on the right side of each panel.
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of viral glycoproteins that are involved in the interaction with viral
receptors is known to affect the ability of virions to react with
virus-neutralizing antibodies (2, 41). To test whether this phe-
nomenon occurs in the case of PRRSV, the PRRSV GP5 mu-
tants with altered glycosylation patterns (FL-N34A, FL-N51A,
and FL-N34/51A) were compared with wt PRRSV (FL-12) in
their ability to be neutralized by convalescent antisera.
Towards this end, we used convalescent antisera (47 days
postinfection) from four animals that had been infected with
wt PRRSV. Similar doses (2,000 TCID50) of infectious
PRRSV GP5 mutants (FL-N34A, FL-N51A and FL-N34/51A)
as well as of the infectious clone-derived wt PRRSV (FL-12)
were used as the challenge virus in serum neutralization assays
following our standard assay protocol and the set of four anti-wt
PRRSV (FL-12) sera used as references. Table 2 shows the dif-
ferent endpoint neutralizing titers obtained.
Normally, a wt PRRSV convalescent-phase serum sample
collected at 47 to 54 days postinfection contains moderate
levels of wt PRRSV neutralizing activity (1:8 to 1:32) (Tables
2 and 3), reflecting the relatively weak and sluggish character
of the neutralizing antibody response that is typical of infec-
tions with wt PRRSV (31). However, the use of hypoglycosyl-
ated PRRSV mutants (which lack one or two glycan moieties
on the GP5 ectodomain) as the challenge virus in the serum
neutralization assays seems to have significantly enhanced the
endpoint of the reference sera, with endpoint titer enhance-
ment ranging from 6- to 22-fold (Table 2). This observation
clearly suggests that the removal of one or particularly two of
the glycan moieties increases the accessibility of the neutraliz-
ing epitope to specific antibodies. These results appear to in-
dicate the presence of significant amount of PRRSV-neutral-
izing antibodies in the wt PRRSV-infected convalescent-phase
sera that would otherwise have been undetectable because of
the use of wt PRRSV containing fully glycosylated GP5 in
typical serum neutralization assays.
Influence of hypoglycosylation of GP5 on PRRSV’s ability to
induce neutralizing antibodies in vivo. One remarkable effect
that has been reported in the literature is that carbohydrate
removal from a viral envelope glycoprotein leads to production
of high titers of neutralizing antibodies against the mutant
virus when this mutant is used for in vivo inoculation of the
host, in some cases also inducing higher titers of antibody to
the wt virus than the wt virus itself (40). We infected groups of
pigs with identical doses of either wt PRRSV (FL-12) or one of
the mutants with altered glycosylation patterns.
Interestingly, clinical and virological assessment of the in-
fection by evaluation of rectal temperature and evaluation of
viremia at days 4, 7, and 10 postinfection indicated a similar
pattern of infection in all groups, as previously described for
FL-12 (49) without evidence of virulence attenuation or exac-
erbation for either of the mutants (data not shown). However,
sequential sampling of serum from these animals for 48 days
indicated pronounced differences between wt PRRSV and the
mutants in the kinetics of induction of a PRRSV-neutralizing
antibody response (Tables 3 and 4). The mutants developed
early and more robust homologous neutralizing antibody re-
sponses than that developed by wt PRRSV, to the point where,
in the case of the mutants, the characteristically weak and
sluggish nature of the PRRSV-neutralizing antibody response
appears to have been corrected (Table 4).
The kinetics of the appearance of mutant-homologous neu-
tralizing antibodies (Table 4) indicates a more regular neutral-
izing antibody seroconversion consistent with that described
for other viral infections such as influenza virus or pseudora-
bies virus but not for PRRSV (31). Of utmost importance is the
fact that the infection with GP5 glycosylation mutants induced
a wt PRRSV-specific neutralizing antibody response that is
significantly higher than the response with wt PRRSV itself.
The mutant viruses FL-N34A and FL-N51A induced fivefold-
higher (P  0.05) levels of neutralizing antibody titer against
wt PRRSV than did wt PRRSV itself, while mutant FL-N34/
51A induced a sixfold-higher (P  0.01) titer of wt PRRSV-
neutralizing antibodies than did wt PRRSV itself (Table 3).
DISCUSSION
In the present study, we examined the influence of glycosyl-
ation of GP5 of PRRSV on recovery of infectious virus and its
role in the ability of the mutant viruses to be neutralized by
antibodies and in inducing neutralizing antibodies in vivo. We
TABLE 2. Effect of alteration of glycosylation pattern of PRRSV
GP5 on the ability of the infectious virion to react
with neutralizing antibodiesa
Animal
no.
Endpoint with PRRSV strain:
Wt PRRSV (FL-12) FL-N34A FL-N51A FL-N34/51A
11404 1:32 1:256 1:256 1:32,768
11346 1:8 1:64 1:256 1:16,384
11457 1:16 NDb 1:128 1:2,048
11407 1:8 ND 1:64 1:2,048
a Data are inverse endpoint dilutions showing neutralization. Animals were
infected with 105 TCID50 of wt PRRSV FL12, and serum samples were taken 47
days postinfection.
b ND, not determined.
TABLE 3. Effect of altered GP5 glycosylation pattern on ability of
PRRSV strains to induce neutralizing antibodies to wt PRRSV
Strain
Geometric mean endpoint at
indicated day postinfection
0 14 21 48
Wt PRRSV (FL-12) 1.0 1.0 3.2 25.4
FL-N34A 1.0 1.0 4.0 128.0
FL-N51A 1.0 1.0 4.0 128.0
FL-N34/51A 1.0 1.0 5.0 161.3
TABLE 4. Effect of altered GP5 glycosylation pattern on ability of
PRRSV strain to induce neutralizing antibodies
to a homologous strain
Strain
Geometric mean endpoint at
indicated day postinfection
0 14 21 48
Wt PRRSV (FL-12) 1.0 1.0 3.2 25.4
FL-N34A 1.0 4.0 128 8,192
FL-N51A 1.0 4.0 128 2,048
FL-N34/51A 1.0 4.0 64 4,096
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have found that all three potential glycosylation sites (N34,
N44, and N51) in GP5 are used for the addition of glycan
moieties. Our results reveal that glycan addition at the N44 site
is most critical for the recovery of infectious virus. Further-
more, our results show that PRRSVs containing hypoglycosy-
lated forms of GP5 are exquisitely sensitive to neutralization by
antibodies and that the mutant viruses induce significantly
higher levels of neutralizing antibodies not only to the homol-
ogous mutant viruses but also to wt PRRSV.
Confirmation that all three potential N-linked glycosylation
sites are used for glycan addition in GP5 was provided by using
mutants with alterations at single or multiple sites (Fig. 2).
Biochemical studies showed that the PRRSV GP5 protein,
when coexpressed with M protein in transfected cells, contains
Endo H-sensitive high-mannose-type glycans. The observation
that the majority of GP5 incorporated into virions is resistant
to Endo H (Fig. 4A) whereas GP5 expressed in the presence of
M protein in transfected cells is fully Endo H sensitive is
intriguing. It is possible that GP5 expressed in the presence of
M protein in transfected cells accumulates mostly in the en-
doplasmic reticulum or in the cis-Golgi region and therefore
remains Endo H sensitive. However, in PRRSV-infected cells,
GP5 may interact with additional viral proteins and the trans-
port of GP5 beyond the endoplasmic reticulum or cis-Golgi
apparatus is facilitated through the formation of complexes
with other viral proteins. Consistent with this interpretation,
we have observed that in wt or mutant PRRSV-infected cells,
GP5 protein is also resistant to Endo H.
We suggest that GP5, which is synthesized in the endoplas-
mic reticulum in infected cells, is transported to the medial
and/or trans-Golgi region where the majority of GP5 molecules
acquire Endo H resistance prior to being incorporated into
PRRSV virions. Several studies with arteriviruses, including
PRRSV, suggest that GP5 and M protein form a heterodimer,
which may play a key role in viral infectivity (13, 15, 28). In
EAV and LDV, direct interaction of GP5 and M protein
through the formation of disulfide bridges has been demon-
strated (13, 15). Such interactions may occur prior to further
processing of N-linked oligosaccharide side chains, presumably
before GP5 is transported out of the endoplasmic reticulum or
the cis-Golgi compartment.
It is interesting that the pattern of Endo H resistance of GP5
incorporated into wt and mutant virions is different. While the
majority of GP5 molecules in wt PRRSV were Endo H resis-
tant, most of the GP5 molecules in the single-site mutant
virions (FL-N34A and FL-N51A) were Endo H sensitive (Fig.
4A). Furthermore, of the two glycan moieties in these mutants,
only one was sensitive, while the other was resistant. The dou-
ble mutant (FL-N34/51A) virion also incorporated GP5 that
contained glycans, some of which were also sensitive to Endo
H. These data are consistent with the interpretation that wt as
well as mutant PRRSV virions incorporate a mixed population
of GP5 molecules that contain different glycan moieties at
different sites. Previous studies demonstrating incorporation of
differentially glycosylated forms of GP5 into wt PRRSV virions
(28) further strengthen our interpretation.
From the pattern of Endo H sensitivity of GP5 incorporated
into the virions, it is tempting to speculate that the N44 site
may contain the Endo H-resistant glycans, although some GP5
molecules with Endo H-sensitive glycans at this site were in-
corporated into virions. Whether this unusual pattern of gly-
cans at various sites in GP5 and incorporation of various forms
of GP5 into virions has any relevance to the pattern of immune
response seen in PRRSV-infected animals remains to be in-
vestigated.
In a recent study, it was shown that of the two N-linked
glycosylation sites (N46 and N53) in GP5 of Lelystad PRRSV,
glycosylation of N46 residue was strongly required for virus
particle production. Infectious virus yield was reduced by ap-
proximately 100-fold by a mutation at N46 (53). Our results
suggest that glycan addition at N44 (for North American
PRRSV) is absolutely essential for recovery of infectious
PRRSV. It is possible that the European and North American
isolates of PRRSV differ somewhat in their requirements for
N-linked glycosylation for production of infectious viruses. In
this regard, it is of note that the Lelystad virus contains only
two N-linked glycosylation sites, whereas the North American
isolates we have used in this study contain three such sites.
GP5 is the most important glycoprotein of PRRSV involved in
the generation of PRRSV-neutralizing antibodies and protective
immunity. Our results reveal that the absence of glycans at resi-
dues 34 and 51 in the GP5 ectodomain, while generating viable
PRRSV mutants, enhances both the sensitivity of these mutants
to neutralization by antibodies and the immunogenicity of the
nearby neutralization epitope. The immediate effect of the ab-
sence of glycans in GP5 of mutant PRRSVs has been increased
sensitivity of the viruses to neutralization by convalescent-phase
sera from pigs infected with wt PRRSV (Table 2).
Studies with human immunodeficiency virus type 1 and sim-
ian immunodeficiency virus have shown that acquisition or
removal of glycans in the variable loops of gp160 modifies their
sensitivity to neutralization (5, 7, 30). Therefore, it has been
postulated (41) that glycans play at least two types of essential
roles during biosynthesis of viral envelope glycoproteins. In
one case, lack of glycans entails defects of the glycoprotein and
thus in the overall viability of the viral strain. We postulate that
the glycans at N44 of PRRSV GP5 serve a similar role. In the
second case, the glycans potentially serve to shield viral pro-
teins against neutralization by antibodies (41). For PRRSV
GP5, glycans at N34 and N51 may have a similar role. In the
case of human immunodeficiency virus, “glycan shielding” is
postulated to be a primary mechanism to explain evasion from
neutralizing immune response, ensuring in vivo persistence of
human immunodeficiency virus (50).
This invites us to draw some parallels with PRRSV. Infec-
tion with PRRSV, which is known to persist for several months
in individual animals (3, 52), presents an unusual behavior in
terms of induction of virus-specific neutralizing immune re-
sponse (31). It is well documented that animals infected with
PRRSV usually take longer than normal to establish a detect-
able PRRSV-neutralizing antibody response. Once estab-
lished, this PRRSV-neutralizing response is weak, and varies
significantly from animal to animal (31, 38). The delay in neu-
tralizing antibody response has been postulated to be due to
the presence of a nearby immunodominant decoy epitope
(amino acid positions 27 to 30), which evokes a robust, early,
nonprotective immune response that masks and/or slows the
response to the neutralizing epitope (amino acid positions 37
to 45) (26, 38). While this is a plausible explanation for the
atypical character of the PRRSV-neutralizing antibody re-
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sponse, it remains to be tested. In our laboratory, deletion of
the decoy epitope has consistently proven lethal to the recov-
ery of infectious PRRSV (I. H. Ansari et al., unpublished
results), making it difficult to test this hypothesis.
It is possible that an alternative or complementary mecha-
nism to explain the peculiar nature of the PRRSV-neutralizing
response could be envisioned by the glycan-shielding phenom-
enon proposed for the human and simian immunodeficiency
viruses (22, 50). The use of mutant PRRSVs lacking one or two
glycan moieties in our studies provides evidence for the first
time of the presence of large amounts of PRRSV-neutralizing
antibodies in the sera of wt PRRSV-infected animals that were
otherwise undetectable because of the use of wt PRRSV in the
serum neutralization assays. The PRRSV-neutralizing anti-
bodies, while present in the host’s response, are unable to react
with the infecting wt PRRSV virions due to blocking or shield-
ing of the neutralizing epitope by the glycan moieties on GP5.
One important precedent for neutralization escape by gly-
cosylation of glycoproteins in arteriviruses has been described
for LDV. It is highly resistant to antibody neutralization due to
the heavy glycan shielding of its major glycoprotein, VP-3 (8).
However, certain naturally occurring strains of LDV are highly
susceptible to neutralization due to loss of two glycosylation
sites on the ectodomain of VP-3. Interestingly, this neutraliza-
tion-sensitive phenotype correlates with a high degree of neu-
rotropism in the host acquired by these easily neutralizable
LDV strains. Such enhancement of neuropathogenicity prob-
ably reflects the facilitation of interaction of the viral glyco-
proteins with receptors in neural cells, possibly due to the
absence of glycan shielding (8).
In the young-pig model that we used for inoculation with
PRRSV, we were not able to detect pathogenic differences
between any of the mutant PRRSVs and wt PRRSV, although
we limited our observations to temperature and viremia mea-
surements. It is possible that under different experimental con-
ditions (i.e., in a pregnant-sow model), some alterations in the
pathogenicity of these mutant PRRSVs might be observed. It
is not known whether naturally occurring hypoglycosylated
PRRSV strains are common, although previous reports have
suggested their presence (27, 39).
A remarkable observation in our experiments has been that
the GP5 mutants, when infecting pigs in vivo, can outperform
wt PRRSV in their ability to mount a sizable wt PRRSV-
neutralizing response at late phases of infection (Table 3). Our
results seem to mimic one of the most dramatic effects of viral
glycoprotein carbohydrate removal so far reported in the lit-
erature by Reitter et al. (40). These authors observed that
rhesus monkeys infected with simian immunodeficiency virus
mutants lacking selected glycans moieties mount higher neu-
tralization responses not only against the mutant virus but also
against wt simian immunodeficiency virus than those caused by
the wt virus itself. In a parallel scenario, we have observed not
only higher neutralizing titers against homologous PRRSV
mutants but also sizable titers against wt PRRSV (Table 3). In
addition, the response occurred earlier, with neutralizing titers
detectable at 14 days postinfection, an observation not typically
noted with wt PRRSV infection (Table 4).
The increased neutralization of wt PRRSV by sera from pigs
infected with the PRRSV mutants suggests that glycans were
masking a neutralizing epitope(s) that does not induce neu-
tralizing antibodies when glycans are present. This observation
has great significance for the design of better, more efficacious
PRRSV vaccines, suggesting that new, rationally designed vac-
cines should carry modifications in the glycosylation pattern of
GP5 in order to enhance the production of neutralizing anti-
bodies. In addition, it will be important to study the effects that
this removal of carbohydrates from immunologically promi-
nent glycoproteins of PRRSV may have on increasing serum
neutralization titers not only to the homologous immunizing
strain, but also to diverse unrelated PRRSV strains.
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